KSC · 102460.KS
REYON Pharmaceutical Co., Ltd.
₩9,370+₩10 (+0.11%)
REYON Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.02% below the high.
Loading market information…
KOE · 119610.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Interojo Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Interojo Inc.’s forward annual dividend is ₩650 per share, paid annual. The forward yield is 4.66% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Interojo Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of ₩513. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Interojo Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Interojo Inc. manufactures and sells contact lenses in South Korea and internationally. It offers silicone hydrogel lens, premium hydrogel lens, hydrogel lens, color lens, RGP, and other products. The company was founded in 2000 and is headquartered in Pyeongtaek-si, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 12:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Feb 27, 2025 |
| -₩402 |
| ₩23.79B |
| Q3 2024 | Nov 15, 2024 | ₩279 | ₩33.1B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩9,370+₩10 (+0.11%)
REYON Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.02% below the high.
₩7,650-₩40 (-0.52%)
Samil Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.51% below the high.
₩10,510-₩80 (-0.76%)
JW Lifescience Corporation’s quoted price sits in the lower half of its reported 52-week range, 32.54% below the high.
₩8,070-₩160 (-1.94%)
Hana Pharm Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.3% below the high.
₩5,090-₩220 (-4.14%)
AptaBio Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.26% below the high.
₩8,600-₩230 (-2.6%)
Jeil Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 55.42% below the high.
₩9,780+₩110 (+1.14%)
DIO Corporation’s quoted price sits in the lower half of its reported 52-week range, 49.59% below the high.
₩5,020-₩40 (-0.79%)
DongBang Medical’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
